http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고 Mn-Cr 강의 조사손상에 미치는 전자선 조사 온도의 영향
배동수,정호신,강창용,남승훈,이해무 대한금속재료학회 2004 대한금속·재료학회지 Vol.42 No.3
The effect of electron-beam irradiation temperature on irradiation damage of 12%Cr-15%Mn austenitic steel for structural material of nuclear and/or fusion reactors from the point of view of the reduced activation was investigated by using the 1,250 keV HVEM and an energy dispersed X-ray analyzer(EDX) in a 200 keV FE-TEM with beam diameter of about 0.5 nm. Void formation was not observed in irradiated specimen. The dislocation loop growth was observed and the density and size of dislocation loop were increased with irradiation dose. Irradiation-induced segregations of Cr and Mn at grain boundary were also observed by electron-beam irradiation condition. The amount of Mn segregation was increased with irradiation temperature, however, segregation phenomenon was disappeared in the case of Cr.
Nahm, Dong-Ho,Cho, Su-Mi,Kim, Myoung-Eun,Kim, Yeo-Jin,Jeon, Sook-Yeong The Korean Academy of Asthma, Allergy and Clinical 2014 Allergy, Asthma & Immunology Research Vol.6 No.1
<P>The management of severe recalcitrant atopic dermatitis (AD) is a challenging issue for clinicians and patients. We hypothesized that repeated intramuscular injections of autologous immunoglobulin (autologous immunoglobulin therapy: AIGT) might induce clinical improvements in patients with AD by stimulation of the active immune response to antigen-binding-site of pathogenic antibodies. We tried AIGT in 3 adult patients with severe recalcitrant AD whose clinical conditions could not be effectively controlled by medical treatments (including oral cyclosporine) for more than 2 years. Autologous immunoglobulin was purified from the autologous plasma by affinity chromatography using Protein A. The patients were treated by an intramuscular injection of 50 mg of autologous immunoglobulin twice a week for 4 weeks. A clinical severity score of AD (SCORAD value) showed a decrease greater than 30% at 8 weeks after the initiation of AIGT compared with the baseline before the initiation of AIGT in all 3 patients with severe recalcitrant AD. No significant side effects from treatment were observed. Further studies with larger numbers of patients are required to evaluate the clinical usefulness of AIGT for AD.</P>
Personalized Immunomodulatory Therapy for Atopic Dermatitis: An Allergist`s View
( Dong Ho Nahm ) 대한피부과학회 2015 Annals of Dermatology Vol.27 No.4
The current standard medical therapy for atopic dermatitis (AD) mainly focuses on symptomatic relief by controlling skin inflammation with topical corticosteroids and/or topical calcineurin inhibitors. However, the clinical efficacy of pharmacological therapy is often disappointing to both patients and physicians. The terminology of AD contains a historical meaning of eczematous dermatitis caused by hypersensitivity reaction to environmental inhalant or food allergen. Complex interrelationships among genetic abnormalities, environmental triggers, skin barrier defects, and immune dysfunction resulting in a vicious domino-circle seem to be involved in the development and maintenance of AD. In the viewpoint of AD as an allergic disease, complete avoidance of clinically relevant allergen or induction of specific immune tolerance through administrations of allergen (allergen immunotherapy) can provide clinical remission by breaking the vicious domino-circle maintaining a chronic disease state. In recent clinical studies, monoclonal antibodies including the anti-interleukin-4 receptor antibody and anti-B cell antibody induced significant clinical improvements in patients with AD. The detailed characteristics of immune dysfunction are heterogeneous among patients with AD. Therefore, a personalized combination of immunomodulatory therapies to reduce hypersensitivity (allergen immunotherapy) and correct immune dysfunction (monoclonal antibody therapy) could be a reasonable therapeutic approach for patients with AD. Future immunomodulatory therapies for AD should be developed to achieve long-term treatment-free clinical remission by induction of immune tolerance. (Ann Dermatol 27(4) 355∼363, 2015)
Nahm, Dong-Ho,Kim, Hee-Yeon,Yim, Hyunee,Koh, Young-Yoon,Park, Hae-sim 아주대학교 의과학연구소 1998 아주의학 Vol.3 No.2
Autoantibodies to neuronal cell antigen have been proposed to be responsible for central nervous system (CNS) disease in patients with systemic lupus erythematosus (SLE). However, the target antigen molecules in human brain tissue responsible for the development of CNS dysfunction in SLE patients have not yet been identified. To identify the specific human brain proteins associated with CNS dysfunction in SLE, we measured the autoantibodies to both human brain proteins and extractable nudear antigen from calf thymus by ELISA, and characterized the human brain autoantigen by immunoblot analysis using sera from 15 SLE patients with diffuse CNS manifestation, 14 SLE patients without CNS manifestation, and 16 healthy subjects as controls. Although the levels of autoantibodies to both human brain proteins and extractable nudear antigen were higher in SLE patients than the controls (p< 0.05), there were no significant differences in the levels between SLE patients with or without CNS manifestation (p> 0.05). On immunoblot analysis, autoantibodies to 38 kDa protein in human brain tissue were positive in 6 (86%) of 7 SLE patients with CNS manifestation, 2 (29%) of 7 SLE patients without CNS manifestation, and one (20%) of 5 controls, and a significant difference in positive rates was noted between two SLE groups (Chi-square test; p< 0.05). In conclusion, the 38 kDa human brain protein may be an important target for autoantibodies in sera of SLE patients with CNS manifestation, and further study is essential to confirm the pathogenic significance of this autoantigen.